pheochromocytoma and paraganglioma
Conditions
Interventions
None listed
Sponsors
University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible participants were adults aged 18 years or older who underwent measurement of pMN/pNMN using the 2-MET Plasma ELISA kit (SML) after its reimbursement from January 2019.
Exclusion criteria
Exclusion criteria: The following cases were excluded from the analysis based on medical record review: (1) use of medications known to interfere with metanephrine measurements (e.g., antidepressants, atypical antipsychotics, sympathomimetic agents); (2) ingestion of foods known to affect metanephrine measurements (e.g., caffeine-containing products, bananas, or vanilla) on the day of blood sampling; (3) specimen collection performed during the treatment of acute illnesses or other clinical conditions likely to cause marked sympathetic activation; (4) cases in which the presence or absence of PPGL could not be definitively determined due to insufficient pathological, imaging, or clinical follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal cutoff values of plasma-free metanephrine and normetanephrine for the diagnosis of pheochromocytoma and paraganglioma, determined by receiver operating characteristic (ROC) analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of the diagnostic performance of plasma-free and urinary fractionated metanephrines assessed by ROC analysis (AUC, sensitivity, and specificity). 2. Comparison of changes in plasma-free fractionated metanephrine levels before and after surgery. | — |
Countries
Japan
Contacts
Public ContactMasato Yonamine
University of Tsukuba Laboratory of Laboratory/Sports Medicine, Institute of Medicine
Outcome results
None listed